Symphogen: Patent for Polyclonal Antibody Compositions for Allergy Treatment

25-Feb-2005

Symphogen A/S announced it was granted a US patent for the development of recombinant polyclonal antibodies, known as symphobodies, to treat and prevent allergic reactions. Symphogen's approach enables the novel delivery of antibody-based drugs intranasally or through pulmonary inhalation. Such topically administered symphobodies prevent allergic reactions by effectively blocking complex allergen antigens. In addition, blocking allergen-specific polyclonal antibodies may be given by injection against serious allergic reactions. Symphogen's unique approach to the treatment of allergy is expected to be superior to current treatments.

"This product patent is an important milestone for Symphogen as it highlights our core technology's potential to produce improved therapeutic compositions comprising truly human antibodies and positions the Company to enter the allergy field. We plan to develop the allergy opportunity further in co-operation with a partner or by out-licensing the technology," says Dr. Kirsten Drejer, Chief Executive Officer of Symphogen.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous